BARD1 shows off latest technology, potentially disrupting exosome research industry
Health & Biotech
Health & Biotech
Link copied to
Biotech company BARD1 Life Sciences (ASX:BD1) just launched its latest product, RUO EXO-NET, at the International Society of Extracellular Vesicles (ISEV) Annual Meeting today.
The EXO-NET is a technology that allows fast, accurate and scalable capture of exosomes from any biological sample, including blood, urine and saliva, in as little as 15 minutes.
The tool will be available for the research community, and has the potential to be embedded into future developments of exosome-based diagnostic and therapeutics applications.
According to research, the global exosome market for diagnostics and therapeutics is expected to reach US$2.3 billion by 2030.
Exosomes are basically cellular vesicles in the human body, which shuttle proteins and genetic information between cells.
These nanoparticles are released from most cells, including cancer cells, into body fluids, and have enormous clinical and commercial potential in the diagnosis and treatment of numerous diseases.
The EXO-NET technology solves the sample preparation problems encountered using traditional exosomes capture methods, by providing fast and accurate capture from any liquid sample.
“The potential of this technology is largely untapped, as only EXO-NET can be customised for the capture of target exosome sub-populations for a range of commercial diagnostic and therapeutic applications,” says BARD1 chief scientific officer, Dr Peter French.
There is increasing interest in exosomes because they contain important molecules such as DNA, RNA, proteins, and lipids.
As such, they provide valuable clues to a person’s health as they contain molecules from the host cells that can be used for diagnosis of diseases, which includes cancer and neurodegenerative conditions such as Alzheimer’s disease.
Explaining the science behind the technology at the ISEV conference today, BARD1’s US-based team said that EXO-NET consists of a multilayered three-dimensional matrix, comprising several exosome-specific antibodies and spacer, and linker molecules.
These molecules interact to maximise specific binding and capture of exosomes from complex biofluids, in a reproducible and scalable manner.
The company explained that exosomes have enormous therapeutic applications, with over 20 biopharma companies currently researching the use of exosomes to treat numerous diseases.
The launch of EXO-NET today will potentially lead to future commercial sales and licensing opportunities for BARD1.
BARD1’s share price has risen by more than 880 per cent in the last six months, after news that its its cancer detection technology is effective in diagnosing breast cancer and ovarian cancer.
Those tests utilised Bard1’s blood probe, SubB2M, which specifically looks for Neu5Gc, a sugar molecule present in several cancers including ovarian.
Currently, the data is only preliminary and involved less than 100 patients, but the results were enough to suggest that there is significant potential for commercialisation.
BARD1 share price chart: